Dysregulation of cellular signaling by HER2 in breast cancer
about
Overexpression of platelet-derived growth factor receptor alpha in breast cancer is associated with tumour progressionApc mutation enhances PyMT-induced mammary tumorigenesisHER2 testing: a review of detection methodologies and their clinical performanceClinical and multiple gene expression variables in survival analysis of breast cancer: Analysis with the hypertabastic survival modelInter-observer reproducibility of HER2 immunohistochemical assessment and concordance with fluorescent in situ hybridization (FISH): pathologist assessment compared to quantitative image analysis.High scFv-receptor affinity does not enhance the antitumor activity of HER2-retargeted measles virus.Activation of AMP-activated protein kinase by temozolomide contributes to apoptosis in glioblastoma cells via p53 activation and mTORC1 inhibition.Adiponectin: a link between obesity and cancer.Key signaling nodes in mammary gland development and cancer: β-catenin.Dmp1α inhibits HER2/neu-induced mammary tumorigenesis.Targeting the ubiquitin-proteasome pathway in breast cancer therapy.Gene expression signatures of peripheral CD4+ T cells clearly discriminate between patients with acute and chronic hepatitis B infection.MMP-9 increases HER2/neu expression and alters apoptosis levels in human mammary epithelial cells (HMEC).Peptabody-EGF: a novel apoptosis inducer targeting ErbB1 receptor overexpressing cancer cells.CKS1BP7, a Pseudogene of CKS1B, is Co-Amplified with IGF1R in Breast Cancers.Abundant expression of mTOR kinase in salivary gland tumors - potentials as therapy target?α-Tocopheryloxyacetic acid is superior to α-tocopheryl succinate in suppressing HER2-high breast carcinomas due to its higher stability
P2860
Q24813774-FD784D06-34FB-4B8E-8D06-5EFFA79930D6Q27310772-4A5DC236-0089-4205-9D39-AC2D703B8438Q28280488-8F130245-AB7D-498F-A5A0-12E632DD2BE3Q29248640-670A2DBB-4CE9-4AD1-B391-3BA8F0BB0737Q33454999-7308BA95-D0A1-4300-A37E-B1001D45982FQ33896979-CB6B73DF-F1D5-4F1F-8797-32664D3EBC54Q34412530-E14678E0-01D0-4D38-BB11-64660816F9E1Q34549919-1B1B38BF-D6D5-4103-AC7E-4DE6E5953E65Q34613461-C99F67DA-E9C3-4A0D-AE45-874678907276Q35035710-2EDDF5F6-658A-4C7C-8FF1-6DF8DE42F304Q36429691-6C86F400-7AEB-4C58-8300-5DCFEA6602BDQ38511081-C9B7C5E1-82AF-4D8D-83A6-33130566CECDQ39300010-16C8A856-E4AB-4021-8D01-E0535240A6EEQ40252778-F9E88F1B-53CA-49BA-AA6F-924306617524Q51037024-767EE651-35AF-4AFC-AB9D-560EB12C9A2DQ54442337-451D1289-177F-4F43-9DFE-C1BA86DA579BQ57649939-76CA6E4B-BD11-4299-8E57-8951504A5FF5
P2860
Dysregulation of cellular signaling by HER2 in breast cancer
description
im Oktober 2003 veröffentlicher wissenschaftlicher Artikel
@de
wetenschappelijk artikel
@nl
наукова стаття, опублікована в жовтні 2003
@uk
name
Dysregulation of cellular signaling by HER2 in breast cancer
@en
Dysregulation of cellular signaling by HER2 in breast cancer
@nl
type
label
Dysregulation of cellular signaling by HER2 in breast cancer
@en
Dysregulation of cellular signaling by HER2 in breast cancer
@nl
prefLabel
Dysregulation of cellular signaling by HER2 in breast cancer
@en
Dysregulation of cellular signaling by HER2 in breast cancer
@nl
P1433
P1476
Dysregulation of cellular signaling by HER2 in breast cancer
@en
P2093
P356
10.1053/J.SEMINONCOL.2003.08.006
P577
2003-10-01T00:00:00Z